[Multicenter study of fluconazole in the treatment of oropharyngeal candidiasis in immunodepressed patients].

Abstract

We have evaluated the efficacy of fluconazole, 50 mg/day for 2 weeks, to treat oropharyngeal candidiasis in immunologically compromised patients. There were overall 27 patients, 25 of which were HIV+ and 2 had neutropenia. The rate of clinical response at the end of therapy, and one week and one month afterwards were 96%, 76% and 64%, respectively. The microbiological eradication was achieved in 36% of patients. The tolerance of the drug was satisfactory, although in 3 cases features of hepatic toxicity were detected. The convenience, good tolerance and clinical efficacy of fluconazole make it the therapy of choice for oropharyngeal candidiasis in immunologically compromised patients.

• Authors: P Muñoz, S Moreno, X Garau, J C López Bernaldo de Quirós, J Berenguer, J More, E Bouza
• Journal: Enfermedades infecciosas y microbiologia clinica (Enferm Infecc Microbiol Clin) Vol. 8 Issue 9 Pg. 560-4 (Nov 1990) ISSN: 0213-005X [Print] Spain
• Vernacular Title: Estudio multicéntrico de fluconazol en el tratamiento de la candidiasis orofaríngea en pacientes inmunodeprimidos.
• PMID: 2099857 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Fluconazole

Topics

• Adult
• Candidiasis, Oral (complications, drug therapy)
• Female
• Fluconazole (adverse effects, therapeutic use)
• HIV Infections (complications)
• Humans
• Immunologic Deficiency Syndromes (complications)
• Male
• Middle Aged
• Neutropenia (complications)
• Prospective Studies